Thursday, could be another great buy day at $2.00. I think this announcement came to late to make an impression. I to agree that the quater was not as bad as Mr. Viscusi, let on with his talk.
It is just a matter of time till the sudy is complete and this stock hit's 6 (six).
*****************post****************
Wednesday April 16 1:27 PM EDT
Vasomedical announces international agreement
WESTBURY, N.Y.--(BW HealthWire)--April 16, 1997-- Vasomedical Inc , manufacturer and marketer of EECP(R)
- a noninvasive treatment for patients suffering with angina pectoris - has entered into an agreement with Nishimura
Kikai Co. Ltd. of Kyoto, Japan, for the sale of EECP(R) into that country. The first units will be placed in major
hospitals in Kyoto, Osaka and Tokyo.
Nishimura Kikai Co. Ltd. (Nishimura) has been in business over 25 years, specializing in the sale of cardiovascular
products to hospitals and clinics throughout Japan. Their product lines include catheters, stents, heart valves and
pumps. Nishimura represents a number of well-known and respected companies in the Japanese market, including St.
Jude Medical, Johnson & Johnson, and Baxter. Nishimura expects to receive regulatory approvals for EECP(R) by
the beginning of 1998, and to commence commercial sales at that time.
"We are very pleased to be working with a company like Nishimura, which is well-suited to represent Vasomedical in
the Japanese market. We are encouraged by the initial reaction of Japanese doctors, and feel that the market potential
for EECP(R) in Japan is quite significant," said Neal Stine, Director of International Operations for Vasomedical.
"With this deal signed and several more to be concluded in the near future, our international sales and marketing
strategies are progressing as planned."
Anthony Viscusi, President and CEO of Vasomedical, stated, "The international marketplace represents an important
part of our future growth. With the appointment of Neal Stine as Director for International Operations, we are
accelerating the process of introducing EECP(R) to key markets around the world. Neal, who is fluent in Spanish and
speaks Japanese, comes to us after eight years with Baxter International, where he held several positions within
Baxter's global businesses, his most recent being Director, Business Planning. We are excited by the interest
generated from outside the U.S. in EECP(R) and look forward to serving those markets."
Except for historical information contained in this news release, the matters discussed are forward looking statements
that involve risks and uncertainties. Among the factors that could cause actual results to differ materially are the
following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity
and supply constraints or difficulties; product development, commercialization or technlological difficulties; the
regulatory and trade environment; and the risk factors reported from time to time in the Company's SEC reports.
Vasomedical is a medical technology company devoted to the development, manufacture and commercialization of
innovative and cost-effective cardiovascular products.
CONTACT: Vasomedical Inc.
Natalie Karp, 516/997-4600 ext. 776 |
